Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.
Dmitry Goldenberg
Advertisement
Partner at Simon-Kucher, New York.
Articles by Dmitry Goldenberg
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
AI has Redefined Healthcare Communication — and There’s No Opting Out
2
Novo Nordisk Signs Deal with Hims & Hers
3
How FDA's Removal of the Two-Trial Requirement Affects Development Programs
4
Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time
5